Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
News Medical

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. Scientists ...
Business Insider

Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s ...
Hosted on MSN

MERTK-targeting drug shows strong AML suppression in lab tests

Researchers at VCU Massey Comprehensive Cancer Center have developed an antibody-drug conjugate, RGX-019-MMAE, that targets the MERTK receptor in acute myeloid leukemia (AML). In preclinical models, ...
GEN

Engineered Bone Marrow Model Advances CRISPR-CAR T Research in AML

Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute ...
Cure Today

FDA Grants Fast Track Designation to AUTX-703 In R/R AML

AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...